Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 701–800 of 1,000
Rauf, A., Ibrahim, M., Al-Awthan, Y. S., Bahattab, O. S., Hemeg, H. A., Khalil, A. A., Khalid, A., Shahid, S., Gull, H., Jan, M. S., et al. (2026) · Plant Biosystems - An International Journal Dealing with all Aspects of Plant Biology · doi:10.1007/s44473-026-00141-5 · Cited by 1
“The cholinergic neurotransmission plays a critical role in cognition and suppressing inflammatory processes (Chen et al. 2022).”
Onyekwere, O., Fakola, E. G., Elebo, A., & Faloye, K. O. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100337 · Cited by 1
Neuroprotective Effects of Carnosine Against Corticosterone‐Induced Depression and Memory Impairment
Elahi, M., Samad, N., Irfan, A., Manzoor, N., Ahmed, M. Z., Матеев, Е., & Jardan, Y. A. B. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71837 · Cited by 1
“Simultaneously, the degeneration of cholinergic neuron, not only reduced acetylcholine (ACh) function but also contribute in the cognitive deficits and indicative of a role of neuroin-flammation and cholinergic damage in dementia and/or memory impairment (Chen et al. 2022).”
Aktar, B. S. K., Karaküçük‐İyidoğan, A., Tatar, G., Oruç‐Emre, E. E., Sıcak, Y., Bakırdöven, A., Turgut‐Solak, Z. D., & Ozturk, M. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2665469 · Cited by 1
El-Naggar, M. H., Al‐Hussain, S. A., Farag, B., Ebaid, M. S., Alhilal, M., Zaki, M. E. A., Alhilal, S., & Gomha, S. M. (2026) · Die Naturwissenschaften · doi:10.1007/s00114-026-02112-4 · Cited by 1
“Early interest in this scaffold was stimulated by natural quin - azolinone alkaloids (e.g., febrifugine and dehydroevodi-amine (DHED, I)), which showed anti-dementia potential and AChE inhibitory activity (Abualassal et al. 2025; Chen et al. 1816; Fu et al. 2022).”
Shukla, S., & Singh, R. K. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11933-5 · Cited by 1
Ben‐Azu, B., Amenotie, A. J., Esuku, D. T., Chijioke, B. S., Adebayo, O. G., Onuelu, J. E., Nekabari, M. K., Lawrence, E. O., & Oyovwi, O. M. (2026) · Brain Disorders · doi:10.1016/j.dscb.2026.100320 · Cited by 1
Behzad, F., Leili, F. R., Ebrahimi, M. J., Moafi, M., Kenari, P. B., Alizadeh, A., Adeli, S., Khosravani, M., Kouhbanani, M. A. J., & Fahanik‐Babaei, J. (2026) · BioMedical Engineering OnLine · doi:10.1186/s12938-026-01572-z · Cited by 1
Soto‐Mercado, V., Mendivil‐Perez, M., Velez‐Pardo, C., & Jiménez-Del-Río, M. (2026) · Organoids · doi:10.3390/organoids5020017 · Cited by 1
“However, none of these hypotheses have been proven conclusively, and some remain controversial (e.g., [19–22].”
Thummajitsakul, S., Klinhom, S., Engchuan, Y., Saikamkong, A., & Silprasit, K. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103539 · Cited by 1
From artery to memory: a comparative review of vascular cognitive impairment surgical models
Kane, M. M., Sneed, S. E., & Kaiser, E. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1861974 · Cited by 1
“…AMPA-silent synapse development, however, impairment of nicotinic Ach receptors in BCCAGO may indicate a pertinent role of synapse failure and neurovascular uncoupling as a driving force behind cognitive decline and should be explored within this model (Lecordier et al., 2021; Chen et al., 2022).”
Bindra, S., Jeong, W. K., Kabier, M., Kumar, S., Sudevan, S. T., Vishwakarma, H. C., Parambi, D. G. T., Maliyakkal, N., Kumar, U., Pappachen, L. K., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71405 · Cited by 1
“Historically considered a peripheral backup for AChE, BChE has emerged as a significant therapeutic target, especially for Alzheimer’s disease (AD) [3]. particularly in the cortex and hippocampus [4].”
Liao, Q., Wang, X., Duan, Y. B., Guo, L., He, S., Lyu, W., Shi, J., Fu, R., Zhang, H., Han, Y., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00302 · Cited by 1
Lotfy, E. M., & Seliem, I. A. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110163 · Cited by 1
Djemil, R., Benslama, O., Touzout, N., Bensalah, B., Lekmine, S., Messai, A., Ghouari, L., EL-BELTAGI, H. S., Al‐Dossary, O., Alsubaie, B., et al. (2026) · Notulae Botanicae Horti Agrobotanici Cluj-Napoca · doi:10.15835/nbha54215242 · Cited by 1
Therapeutic Potential of Kuwanon G: From Bioactivities to Network-Level Mechanisms
Aydemir, E. A., Şimşek, B., Acar, A., Kilit, A. C., & Köse, E. O. (2026) · Molecules · doi:10.3390/molecules31132292 · Cited by 1
Kumar, R., Sinha, S., & Babu, M. A. (2026) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2026.112224 · Cited by 1
Sanjay, S., Sood, R., & Lee, H. (2026) · Molecules · doi:10.3390/molecules31132327 · Cited by 1
“Cholinergic transmission impairment can cause cognitive decline linked to aging and dementia, and patients with Alzheimer’s disease (AD) have been reported to have lower levels of ACh in the brain owing to the loss of cholinergic neurons in the basal forebrain [71].”
An Overview of Dementia and Alzheimer's
Trivedi, R., Maheshwari, R. A., Patel, K. P., Bhandari, S., Hadia, R., Goyal, S., & Soni, R. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815523126010005 · Cited by 1
MINERVA: a public XAI-powered platform advancing multi-target discovery in Alzheimer’s disease
Gambacorta, N., Trisciuzzi, D., Mastrolorito, F., Leonetti, F., Altomare, C., de Candia, M., Catto, M., Amoroso, N., Ciriaco, F., & Nicolotti, O. (2026) · Journal of Cheminformatics · doi:10.1186/s13321-026-01253-y · Cited by 1
Akca, S., Erdağı, S. İ., Sait, S. A. R. I., & ÖZBAĞCI, D. İ. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110233 · Cited by 1
Phullay, P., Panwar, R., Bajwa, S., Wadhwa, K., Chauhan, P., Pahwa, R., Kriplani, P., Rajak, H., Awasthi, R., & Dureja, H. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00616-z · Cited by 1
Yasir, M., Park, J. H., Han, E., Park, W. S., Han, J., Choe, J., & Chun, W. (2026) · Pharmaceuticals · doi:10.3390/ph19071120 · Cited by 1
Delirium Superimposed on Dementia
Eshmawey, M. (2026) · Swiss Archives of Neurology Psychiatry and Psychotherapy · doi:10.3390/sanpp176020008 · Cited by 1
Silkis, I. G. (2026) · Integrative Physiology · doi:10.33910/2687-1270-2026-7-1-46-76 · Cited by 1
Pharmacological Effects and Molecular Mechanisms of Lignans in the Treatment of Alzheimer’s Disease
Sun, L., Zhu, X., Fan, C., Wang, Y., Chen, Q., Zhang, L., Zhang, Y., & Liu, Y. (2026) · Molecules · doi:10.3390/molecules31152594 · Cited by 1
Dragomir, A.-F., Stoleru, S., Barbu, A. C., Zugravu, A., Dumitrescu, M. C., Moraru, M. V., Ciuca, L.-N., Fratea, S., Dobre, C. E., Stoleru, C. M., et al. (2026) · Biomolecules · doi:10.3390/biom16081102 · Cited by 1
“…neurotransmission is a well-recognized contributor to cognitive decline in neurodegenerative disorders, most notably Alzheimer’s disease, in which early degeneration of basal forebrain cholinergic neurons and reductions in choline acetyltransferase activity have been consistently reported [1–4].”
InfluentialHussain, R., Sarfraz, H., Azam, U., Hasnat, M., Khan, S., Asiri, Y. M., & Khan, M. H. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147344 · Cited by 1
Taherkhani, A. M., Şenol, H., Valizadeh, Y., Ghafouri, S. N., Dastyafteh, N., Aktaş, A., Sadeghian, N., Moradkhani, F., Larijani, B., Biglar, M., et al. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01075f · Cited by 1
Ahmed, S., Allam, A. T., Eid, O., Zaki, E. S., Shaheen, A. M., Al-Nazer, M. A., Shalaby, M. E., El‐Dessouki, A. M., Kotb, S. S., El‐Shiekh, R. A., et al. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03640 · Cited by 1
The future of functional foods and byproducts in curing diseases
Rahman, R., Zahid, A. H. M., Das, T. C., Karim, Z., Sayeed, I. M., Rauf, A., & Shah, S. M. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34071-0.00019-1 · Cited by 1
Os caminhos de um estudo de caso sobre a depressão na umbamda
Pires, H. K. G. (2014) · Cadernos de Campo Revista de Ciências Sociais · Cited by 1
Comparing machine learning models for acetylcholine esterase inhibitors
Yucel, M. A. (2022) · Bioorganic & Medicinal Chemistry Reports · doi:10.25135/bmcr.29.22.06.2483 · Cited by 1
Abdulkhader, J., Ummer, A., Kareem, S., Sebastian, G., Nambiar, J. J., Mukundan, M., Lakshmi, A., Gopalakrishnan, A., & Narayanan, S. E. (2023) · Journal of Pharmacy and Allied Medicine · doi:10.58985/jpam.2023.v01i02.06 · Cited by 1
Croton hirtus attenuating streptozotocin-induced neuroinflammation in rats
Prakash, R., Rajangam, J., Cheriyan, B. V., & Dharmian, J. P. (2023) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2023.10.005 · Cited by 1
Shark fish oil prevents scopolamine-induced memory impairment in an experimental model
Naeem, S., Ali, L., Jaffar, N., Khan, S. S., Shafiq, Y., Suri, S., & Tahir, A. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01320-5 · Cited by 1
Koźmiński, P., & Gniazdowska, E. (2024) · Applied Sciences · doi:10.3390/app14072827 · Cited by 1
Novel Carbazoles as AChE Inhibitors: Synthesis, Molecular Docking and Dynamic Simulation Studies
Khare, E., Fatima, Z., Tiwari, O. P., Patra, J., & Kushavah, U. (2024) · Asian Journal of Chemistry · doi:10.14233/ajchem.2024.31559 · Cited by 1
Kashif, S., Feroze, S. A., & Sethi, A. A. (2024) · International Journal of Biology and Chemistry · doi:10.26577/ijbch2024v17i1-a15 · Cited by 1
“The cholinergic theory implicates reduced acetylcholine synthesis in neuronal degeneration, while the amyloid theory posits extracellular beta-amyloid accumulation as a primary instigator of the disease process [8, 9].”
BackgroundRawat, P., Das, S., Pentela, B., Bansal, P., Lovely, L., & Baghel, D. S. (2024) · The Natural Products Journal · doi:10.2174/0122103155307220240910042807 · Cited by 1
Modulation of tyrosine receptor imposed by estrogen in memory and cognition in female rats
Bajwa, I. K., Sharma, P., & Goyal, R. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115340 · Cited by 1
Biswas, K., Moore, C. M., Rogers, H., Wani, K. A., Mushtaq, A., Pukkila-Worley, R., Higgins, D. P., Walker, A. K., Mullen, G. P., Rand, J. B., et al. (2026) · eLife · doi:10.7554/elife.107726.4 · Cited by 1
Future Barriers and Possible Solutions with Recent Advances in Alzheimer’s Disease
Dwivedi, A. R., & Raghuveer, P. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_21 · Cited by 1
Damayanti, D. S., Iktiarani, A., & Gymnastiar, A. P. (2025) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v9i1.33 · Cited by 1
Fitzpatrick‐Schmidt, T., Mansouri, A., Adamec, J., Klein, J., Coleman, L., Edwards, K. N., Simon, L., Molina, P. E., Salling, M. C., & Edwards, S. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10179-5 · Cited by 1
“…deficiency is one of the hallmarks of AD, a progressive neurodegenerative disorder and the most common cause of dementia, and cholinesterase inhibitors such as donepezil and rivastigmine are prescribed for mild and moderate AD to improve cognitive and behavioral symptoms (Chen et al. 2022).”
Crocin exhibits neuroprotective potential against lipopolysaccharide-induced inflammatory responses
Awadalla, E. A., Mohamed, O. S. A., abdelsadek, A. ر., sultan, H. ر., & El-Kader, A. E.-K. M. A. (2025) · Aswan University Journal of Environmental Studies · doi:10.21608/aujes.2025.353447.1320 · Cited by 1
Anticholinesterases Traits Inbuilt in Buxaceae Plant Extracts against Alzheimer’s Disease
Patočka, J., Sharma, S., Navrátilová, Z., Singh, N., Jelínková, R., Mehboob, N., Olekšák, P., Nepovimová, E., & Kuča, K. (2025) · Current Neuropharmacology · doi:10.2174/1570159x23666250326091016 · Cited by 1
“The highlight of this theory is the progressive loss of cholinergic synapses occurring in the hippocampus and neocortex portions of the brain, leading to memory loss [5].”
The pathophysiological signaling and efficacy of medicinal herbal compounds in Alzheimer’s disease
Darabi, S., Ariaei, A., Gorgich, E. A. C., Rezaei, S., Behruzi, M., Abasian, Z., & Rustamzadeh, A. (2025) · Physiology and Pharmacology · doi:10.61186/phypha.29.1.3 · Cited by 1
Smach, M. A., Hammami, R., Zarrouk, A., Hafsa, J., Charfeddine, B., Limem, K., & Khadhri, A. (2025) · Journal of Medicinal Food · doi:10.1089/jmf.2023.0178 · Cited by 1
“31 Currently, herbal drugs and extracts are being explored for their potential in AD treatment.”
ROLE OF PLANT-DERIVED ALKALOIDS IN NEURODEGENERATIVE DISEASE TREATMENT
Kumar, M. (2024) · International Journal of Pharmaceutical Science and Medicine. · doi:10.70199/ijpsm.2.4.109-117 · Cited by 1
Non-transgenic rodent models of Alzheimer’s disease for preclinical research: a review
Joshi, A., Lehene, S., & Mishra, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10549-5 · Cited by 1
Rahamouz-Haghighi, S., Akaberi, M., Emami, S. A., & Tayarani‐Najaran, Z. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120504 · Cited by 1
Mart, E. J., & Ronald Darwin, C. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115842 · Cited by 1
Alzheimer’s Disease: Pathophysiological and Therapeutical Insights
Tyagi, K., Sarup, P., & Malik, J. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_1 · Cited by 1
Research Letters in Biochemistry
(2016) · Research Letters in Biochemistry · doi:10.1155/rlbc · Cited by 1
Convolutional Neural Networks for Alzheimer’s DiseasePreprint
Hu, J. (2023) · Preprints.org · doi:10.20944/preprints202310.1435.v1 · Cited by 1
Bai, W., Yu, X., Li, Q., Tan, H., Yao, Y., Li, S., Zhang, L., Bai, H., Zhuang, W., Chen, L., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5005556 · Cited by 1
Sharma, A., Bhardwaj, M., Kumar, V., Islam, A., & Prakash, H. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.11.628076 · Cited by 1
Gul, S., Rahman, A. U., Kausar, F., Iqbal, A., Gul, H., Jan, M. S., Abdelbacki, A. M. M., Jan, R., & Kim, K. (2025) · Research Square · doi:10.21203/rs.3.rs-6223687/v1 · Cited by 1
Tel, A. Z., Aslan, K., & Gülçın, İ. (2025) · Research Square · doi:10.21203/rs.3.rs-6213034/v1 · Cited by 1
Jamal, O., & Mukhlif, M. G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5247902 · Cited by 1
The Neural Basis of AgingPreprint
Jackson, B. (2025) · doi:10.33774/coe-2025-fcg76-v3 · Cited by 1
Afzal, M., Sajjad, A., Rehmani, M. B. I., Nasir, S., Waseem, S. M. Y., Akram, M. A., Irshad, I., Bashir, S., & Rahimi, M. (2025) · Research Square · doi:10.21203/rs.3.rs-7521725/v1 · Cited by 1
The Effect of Burn Injuries on The Brain
Allahham, A. (2024) · UWA Profiles and Research Repository (UWA) · doi:10.26182/2kjj-4z63 · Cited by 1
Editorial: Updates on memory modulation in health and disease
Miranda, M., Giachero, M., Weisstaub, N., & Morici, J. F. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1205371
“Interestingly, AD disease leads to a bulk of neuromodulatory changes that impact over several neurotransmitter systems (Fahnestock et al., 2002; Rissman et al., 2007; Dinamarca et al., 2012; Revett et al., 2013; Kandimalla and Reddy, 2017; Wang et al., 2019; Chen et al., 2022).”
BackgroundTargeting Various Pathogenic Pathways for the Development of Anti-alzheimer’s Drugs: An Update
Ambreen, S., Fatima, N., Umar, M., Shaququzzaman, M., Alam, M. M., & Ali, R. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266274924231002110733
Alzheimer Disease is Associated with Isotropic Ocular EnlargementPreprint
Ma, S., Ye, Q., Xiao, C., Guan, H., Du, Z., & Qin, P. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2310.11464
Devara, D., Sharma, B., Torres, M. M., Rodriguez, S., Rodarte, D., & Kumar, S. (2024) · Research Square · doi:10.21203/rs.3.rs-3932047/v1
Functional mechanisms of glycosphingolipids in the central nervous system
Guo, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16156-8.00006-7
Talukder, E. K., Aktaruzzaman, M., Ahammad, F., Tasnim, F., Rahman, M. S., wani, P., Faridi, H. M., Raihan, P., & Farhan, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4774995
Wang, W., Yang, J., Liang, D., Yao, L., & Ma, L. (2024) · Natural Product Research · doi:10.1080/14786419.2024.2334335
“AD-related cognitive deficits showed pathological features including degeneration of cortical cholinergic neurons, deposition of amyloid beta in brain, neuroinflammation and hyperphosphorylation of Tau, etc.(Chen et al. 2022).”
Unraveling The Connection: The Impact Of Obesity On Neurological Diseases
(2024) · Journal of Community Medicine and Public Health Reports · doi:10.38207/jcmphr/2024/jan05010510
Akbari, S., & Heidarieh, N. (2024) · Gene Cell and Tissue · doi:10.5812/gct-145615
Drugs Acting on Autonomic Nervous System
Chattopadhyay, M., & Pal, B. (2024) · Springer eBooks · doi:10.1007/978-981-97-2776-6_4
Cheng, H., Li, A., Yang, P., Zhong, Z., Liu, H., Zhang, L., & Qifeng, M. (2024) · Journal of Food Biochemistry · doi:10.1155/2024/7863464
Alzheimer’s Disease: Possible Causes and New Theories for DiagnosisPreprint
Kaur, S. R. (2024) · doi:10.58445/rars.1650
Advances in neurotransmitter detection and modulation: Implications for neurological disorders
Doke, R. R., Bhagwat, A. A., Tambe, P., Vare, P., More, S., Nagare, S., & Shinde, A. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.035
Understanding the biochemical basis of Alzheimer's disease: A clinical chemistry approach
Naif, N. H., Oudah, H. A. A., & Hammood, M. N. (2024) · International Journal of Advanced Chemistry Research · doi:10.33545/26646781.2024.v6.i2b.234
Do Alzheimer victims live in a different era?
Bazzaz, A. A. (2024) · American Journal of Medical and Clinical Research & Reviews · doi:10.58372/2835-6276.1236
Karakaya, A., Erçetin, T., Çevik, U. A., & Özkay, Y. (2024) · European Journal of Life Sciences · doi:10.55971/ejls.1585832
Ngadena, Y. S. M., Owona, P. E., Ella, F. A., Bilanda, D. C., Yandja, P. C. B., Bindzi, G. M., & Dzeufiet, P. D. D. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5066541
Neural Basis of AgingPreprint
Jackson, B. (2025) · doi:10.33774/coe-2025-fcg76
Functional Proteins/Peptides Targeting to Clear Amyloid‐β for Alzheimer's Disease Therapy
Gao, Z., Hou, R., & Qian, C. (2025) · ChemBioChem · doi:10.1002/cbic.202400912
A Novel Review: Association of Alzheimer's Disease with the SUMO Protein Family
Aydin, B. (2024) · DergiPark
Effect of Alzheimer's Disease on Cholinergic Signaling: Examined using a Kinetic ModelPreprint
Thuraisingham, R. A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5124714
Neurocognitive disorders: Dementias
Grace, J., Burling, J. E., Aduen, P. A., & Gatchel, J. R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780198874799.003.0020
Mashhadi-Sharif, N., Soodi, M., Mirnajafi‐Zadeh, J., Shadboorestan, A., Ebadi-Ramsheh, H., & Bakhtiarzadeh, F. (2025) · Neurochemical Research · doi:10.1007/s11064-025-04365-3
Design, Synthesis and Insilico Studies of Quinoline Derivatives
AnjuJose, M. A. M., Ansari, B. A., & Sadhik, F. (2025) · International Journal of Pharmaceutical Research and Applications · doi:10.35629/4494-100116361640
Physiological Changes Linked with Alzheimer’s Disease and Related Dementias
Payen, A., Bateman, J. R., Miller, D., Muralidhara, S. D., & Bennett, J. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_99-1
Singh, S., Sharma, N., Singh, V. P., & Sharma, A. (2025) · Current Nanomedicine · doi:10.2174/0124681873330947241230054603
Unraveling Alzheimer's: A holistic approach to diagnosis, stages and intervention
Dasari, R. D. R., Bhukya, G., Varadammagari, S. V. S., Gujjala, A. G. A., Mugannagari, P. M. P., Pasala, P. K., Reddy, K. S., & Vattikuti, U. M. R. (2025) · International Journal of Science and Research Archive · doi:10.30574/ijsra.2025.15.1.1078
Ma, C. J. (2025) · Natural Product Sciences · doi:10.20307/nps.2025.31.1.55
The Neural Basis of AgingPreprint
Jackson, B. (2025) · doi:10.33774/coe-2025-fcg76-v2
Ran, N., Liu, J., Xu, J., Zhang, Y., & Guo, J. (2025) · PubMed · doi:10.12122/j.issn.1673-4254.2025.04.14
Syah, V. A., Geralda, R., Sakti, N. S. I., Febriyanti, K., Bokshow, R. V. V., Wulandari, V., Hasanah, S. F., Fadillah, M. Z., Auli, W. N., & Saputro, A. H. (2025) · Pharmacy Reports · doi:10.51511/pr.74
Harshil, H. (2025) · International Journal of Advanced engineering Management and Science · doi:10.22161/ijaems.113.4
Mechanistic Understanding of the Anti-Alzheimer’s Agents with Computational Studies
Joshi, N., Chobe, S., G., S. N. K. R., & Alavala, R. R. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_20
Okeniran, O., Aja, I. G., Ade, B., Ajayi, S., Ajibade, A., & Onaolapo, A. Y. (2025) · Acta Bioscientia Journal of Biomedical and Biological Science Research · doi:10.71181/actabioscientia12310
Vanderlip, C. R., Dunn, S. R., Cefalu, J. S., Ballard, T. M., Wettstein, J. G., & Glavis‐Bloom, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.02.657483
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.